Stockscreener 앱 받기
0.171
6.28%
0.0101
시간 외 거래:
.17
-0.001
-0.58%
전일 마감가:
$0.1609
열려 있는:
$0.157
하루 거래량:
3.35M
Relative Volume:
3.85
시가총액:
$2.29M
수익:
$142.00K
순이익/손실:
$-1.23M
주가수익비율:
0.3672
EPS:
0.4657
순현금흐름:
$-10.62M
1주 성능:
-3.50%
1개월 성능:
-37.25%
6개월 성능:
-88.68%
1년 성능:
-94.04%
1일 변동 폭
$0.1495
$0.19
1주일 범위
$0.1495
$0.19
52주 변동 폭
$0.1495
$3.40
Vivosim Labs Inc Stock (VIVS) Company Profile
명칭
Vivosim Labs Inc
전화
858-224-1000
주소
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.171 | 2.29M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-12-13 | 개시 | H.C. Wainwright | Buy |
| 2017-11-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 개시 | Raymond James | Outperform |
| 2015-08-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 개시 | Jefferies | Buy |
| 2015-06-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Vivosim Labs Inc 주식(VIVS)의 최신 뉴스
Press Releases about Volato Group, Inc. Class A Common Stock (NYSE:SOAR) - FinancialContent
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials - Carroll County Mirror-Democrat
Received 5M from Eli Lilly - Moomoo
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - openPR.com
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity - WBOC TV
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - marketscreener.com
VivoSim Labs (VIVS) CCO buys 10,000 shares outside trading plan - Stock Titan
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now - FinancialContent
VivoSim plans rat liver model to complement human testing - Investing.com
VivoSim Labs to Add Rat Liver Model to NAMkind Platform - Yahoo Finance UK
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - Barchart.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
Big Pharma giant Eli Lilly pays $6M to VivoSim Labs 🤯🔥 $Xiao-I (AIXI.US)$ $CID Holdco (DAIC.US)$ - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - openPR.com
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum - Barchart.com
The Largest Pharma On The Planet Sent Cash to a Micro cap 👀 - Moomoo
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VivoSim Labs, INC. SEC Filing (Aug 21, 2026) - Stock Titan
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - WBOC TV
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - FinancialContent
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
VivoSim: Fiscal Q1 Earnings Snapshot - KTVB
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) Revenue BreakdownMain Composition - Moomoo
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com Nigeria
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
Vivosim Labs Inc (VIVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.35%
자본화:
|
볼륨(24시간):